School of Medicine
Showing 1,281-1,290 of 2,431 Results
-
Anson Lowe
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
-
Henry J. Lowe, MD
Associate Professor of Medicine (General Medical Disciplines) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsMy research in the field of biomedical informatics over the past 30 years has focused on the development of novel uses of information technology and computer science to improve human health. My current interests include the Electronic Health Record (EHR), biomedical knowledge representation, Internet applications in healthcare, clinical data warehouses, clinical data and text mining, academic social networking and the use of information technology to support clinical and translational research.
-
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
-
Janice Lu
Clinical Professor, Medicine - Oncology
BioDr. Janice Lu is Clinical Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. She specializes in the treatment of breast cancer, with expertise in hormone receptor–positive and HER2-positive disease, antibody-drug conjugates, and immunotherapy. Dr. Lu has led and contributed to multiple clinical trials, including playing a key role in the EMERALD trial, which resulted in FDA approval of the first oral SERD for ESR1-mutated ER+/HER2- metastatic breast cancer. Her translational research focuses on liquid biopsy, epigenetics, AI and multiomics approaches to treatment resistance. She has chaired national sessions on precision oncology and holds leadership roles with NRG Oncology and ASCO, including Vice-Chair of the NRG Immunotherapy Subcommittee and Track Leader for ASCO’s Developmental Therapeutics and Targeted Therapy Education Program. She has also served on committees for the National Comprehensive Cancer Network (NCCN) and the Southwest Oncology Group (SWOG).
Dr. Lu completed her Hematology and Oncology fellowship at New York University School of Medicine and earned a PhD in epigenetics under the mentorship of late Dr. David Allis, a pioneer in the field and 2018 Lasker Laureate. Prior to joining Stanford, she was Director of Breast Medical Oncology and led the Circulating Tumor Cell (CTC) Core Lab at Northwestern University Feinberg School of Medicine, before returning to the Bay Area to be with her family and to further expand research and patient-centered care.
